Will need to continue monitori_老虎社区_美港股上老虎

PHBeh
2021-07-03

Will need to continue monitoring this stock

Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer

Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3

Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":152245433,"tweetId":"152245433","gmtCreate":1625302858022,"gmtModify":1633941589021,"author":{"id":4088254217057000,"idStr":"4088254217057000","authorId":4088254217057000,"authorIdStr":"4088254217057000","name":"PHBeh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Will need to continue monitoring this stock</p></body></html>","htmlText":"<html><head></head><body><p>Will need to continue monitoring this stock</p></body></html>","text":"Will need to continue monitoring this stock","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/152245433","repostId":2145065855,"repostType":2,"repost":{"id":"2145065855","kind":"news","pubTimestamp":1624372570,"share":"https://ttm.financial/m/news/2145065855?lang=&edition=full","pubTime":"2021-06-22 22:36","market":"us","language":"en","title":"Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2145065855","media":"Benzinga","summary":"Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 ","content":"<html><body><img height=\"400\" src=\"https://s1.yimg.com/uu/api/res/1.2/ltlG4fUvBh_CREj5p0_99Q--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/Benzinga/45658a46633b4f56b03ea4beab387986\" title=\"\" width=\"600\"/>\n<ul>\n<li><strong>Corcept Therapeutics Incorporated</strong> (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer.</li>\n<li>The trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least two prior lines of therapy.</li>\n<li>2/31 evaluable patients exhibited tumor shrinkage designated as a partial response, a response rate of 6%, while 15 patients achieved stable disease for at least 12 weeks. </li>\n<li>The combination was well-tolerated. </li>\n<li>\"Apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer, and we will not pursue an approval unless we believe our candidate therapy offers a substantial benefit,\" added Joseph K. Belanoff, MD, Corcept's Chief Executive Officer. </li>\n<li>Enrollment for the trial is stopped.</li>\n<li>The will initiate a Phase 2 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in Q1 of 2022. </li>\n<li><strong>Price Action</strong>: CORT shares are down 7.75% at $21.2 during the market session on the last check Tuesday.</li>\n</ul>\n<p><strong>See more from Benzinga</strong></p>\n<ul>\n<li>Click here for options trades from Benzinga</li>\n<li>Biocept Stock Moves Higher On Collaboration With Quest Diagnostics For Liquid Biopsy Testing For Lung Cancer Patients</li>\n<li>Histogen Stock Is Trading Higher As Emricasan Shows Complete, Early Resolution of COVID-19 Symptoms Compared To Placebo</li>\n</ul>\n<p><i>© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.</i></p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/corcept-therapeutics-stock-drops-disappointing-143610894.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer.\nThe trial evaluated relacorilant ...</p>\n\n<a href=\"https://finance.yahoo.com/news/corcept-therapeutics-stock-drops-disappointing-143610894.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/faJeAZl8g9aThgo7fMGTIQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/K1Hoih0PGtqBEZEU1Jog2A--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/45658a46633b4f56b03ea4beab387986","relate_stocks":{"CORT":"Corcept医疗"},"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-stock-drops-disappointing-143610894.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145065855","content_text":"Corcept Therapeutics Incorporated (NASDAQ: CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer.\nThe trial evaluated relacorilant plus nab-paclitaxel in pancreatic cancer patients who had relapsed following at least two prior lines of therapy.\n2/31 evaluable patients exhibited tumor shrinkage designated as a partial response, a response rate of 6%, while 15 patients achieved stable disease for at least 12 weeks. \nThe combination was well-tolerated. \n\"Apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer, and we will not pursue an approval unless we believe our candidate therapy offers a substantial benefit,\" added Joseph K. Belanoff, MD, Corcept's Chief Executive Officer. \nEnrollment for the trial is stopped.\nThe will initiate a Phase 2 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in Q1 of 2022. \nPrice Action: CORT shares are down 7.75% at $21.2 during the market session on the last check Tuesday.\n\nSee more from Benzinga\n\nClick here for options trades from Benzinga\nBiocept Stock Moves Higher On Collaboration With Quest Diagnostics For Liquid Biopsy Testing For Lung Cancer Patients\nHistogen Stock Is Trading Higher As Emricasan Shows Complete, Early Resolution of COVID-19 Symptoms Compared To Placebo\n\n© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","news_type":1,"symbols_score_info":{"CORT":1}},"isVote":1,"tweetType":1,"viewCount":797,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":37,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}